nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—TYK2—obesity	0.498	1	CbGaD
Ruxolitinib—BMPR2—ovarian follicle—obesity	0.00695	0.0434	CbGeAlD
Ruxolitinib—RPS6KA6—hindbrain—obesity	0.0028	0.0175	CbGeAlD
Ruxolitinib—RET—autonomic nervous system—obesity	0.00271	0.017	CbGeAlD
Ruxolitinib—CYP3A4—Sibutramine—obesity	0.00233	0.27	CbGbCtD
Ruxolitinib—Night sweats—Bupropion—obesity	0.00211	0.027	CcSEcCtD
Ruxolitinib—CYP3A4—Benzphetamine—obesity	0.00177	0.204	CbGbCtD
Ruxolitinib—PHKG2—hindbrain—obesity	0.00174	0.0109	CbGeAlD
Ruxolitinib—Herpes zoster—Sibutramine—obesity	0.00173	0.0222	CcSEcCtD
Ruxolitinib—PLK1—respiratory system—obesity	0.00171	0.0107	CbGeAlD
Ruxolitinib—HIPK2—hindbrain—obesity	0.00168	0.0105	CbGeAlD
Ruxolitinib—Pancytopenia—Diethylpropion—obesity	0.00153	0.0196	CcSEcCtD
Ruxolitinib—PLK3—islet of Langerhans—obesity	0.00151	0.00946	CbGeAlD
Ruxolitinib—Herpes zoster—Bupropion—obesity	0.00151	0.0193	CcSEcCtD
Ruxolitinib—DYRK1A—hindbrain—obesity	0.00151	0.00943	CbGeAlD
Ruxolitinib—CYP3A4—Bupropion—obesity	0.0015	0.174	CbGbCtD
Ruxolitinib—Contusion—Sibutramine—obesity	0.0015	0.0191	CcSEcCtD
Ruxolitinib—PRKG2—cardiovascular system—obesity	0.00146	0.00914	CbGeAlD
Ruxolitinib—Pancytopenia—Cimetidine—obesity	0.00146	0.0186	CcSEcCtD
Ruxolitinib—Neutropenia—Cimetidine—obesity	0.00143	0.0183	CcSEcCtD
Ruxolitinib—ANKK1—adrenal gland—obesity	0.0014	0.00873	CbGeAlD
Ruxolitinib—Hypercholesterolaemia—Sibutramine—obesity	0.00138	0.0176	CcSEcCtD
Ruxolitinib—Bone pain—Sibutramine—obesity	0.00136	0.0174	CcSEcCtD
Ruxolitinib—CAMK2G—hindbrain—obesity	0.00134	0.0084	CbGeAlD
Ruxolitinib—RPS6KA6—cardiovascular system—obesity	0.00131	0.0082	CbGeAlD
Ruxolitinib—Contusion—Bupropion—obesity	0.0013	0.0167	CcSEcCtD
Ruxolitinib—PRKG2—pituitary gland—obesity	0.00129	0.0081	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Methamphetamine—obesity	0.00127	0.0162	CcSEcCtD
Ruxolitinib—CYP3A4—Orlistat—obesity	0.00122	0.142	CbGbCtD
Ruxolitinib—Gastrointestinal disorder—Benzphetamine—obesity	0.00122	0.0156	CcSEcCtD
Ruxolitinib—PRKG2—digestive system—obesity	0.00121	0.00759	CbGeAlD
Ruxolitinib—PRKCE—adipose tissue—obesity	0.0012	0.00753	CbGeAlD
Ruxolitinib—Hypercholesterolaemia—Bupropion—obesity	0.0012	0.0154	CcSEcCtD
Ruxolitinib—RPS6KA6—pituitary gland—obesity	0.00116	0.00726	CbGeAlD
Ruxolitinib—MAST1—pituitary gland—obesity	0.00116	0.00726	CbGeAlD
Ruxolitinib—JAK1—islet of Langerhans—obesity	0.00116	0.00726	CbGeAlD
Ruxolitinib—CAMK1—adrenal cortex—obesity	0.00112	0.00702	CbGeAlD
Ruxolitinib—CYP3A4—Cimetidine—obesity	0.0011	0.127	CbGbCtD
Ruxolitinib—DCLK3—pituitary gland—obesity	0.0011	0.00688	CbGeAlD
Ruxolitinib—JAK1—respiratory system—obesity	0.0011	0.00686	CbGeAlD
Ruxolitinib—PLK3—cardiovascular system—obesity	0.00109	0.00684	CbGeAlD
Ruxolitinib—STK16—islet of Langerhans—obesity	0.00109	0.00681	CbGeAlD
Ruxolitinib—PLK4—respiratory system—obesity	0.00109	0.00681	CbGeAlD
Ruxolitinib—PLK1—digestive system—obesity	0.00109	0.00681	CbGeAlD
Ruxolitinib—PRKCE—adrenal gland—obesity	0.00108	0.00675	CbGeAlD
Ruxolitinib—CAMK1D—respiratory system—obesity	0.00107	0.00669	CbGeAlD
Ruxolitinib—Flatulence—Cimetidine—obesity	0.00105	0.0135	CcSEcCtD
Ruxolitinib—DAPK3—islet of Langerhans—obesity	0.00104	0.00651	CbGeAlD
Ruxolitinib—PLK1—adrenal gland—obesity	0.00104	0.00649	CbGeAlD
Ruxolitinib—HIPK2—respiratory system—obesity	0.00102	0.0064	CbGeAlD
Ruxolitinib—PRKG2—endocrine gland—obesity	0.001	0.00627	CbGeAlD
Ruxolitinib—MAP3K19—respiratory system—obesity	0.001	0.00627	CbGeAlD
Ruxolitinib—CLK2—respiratory system—obesity	0.000974	0.00609	CbGeAlD
Ruxolitinib—Dizziness—Methamphetamine—obesity	0.000969	0.0124	CcSEcCtD
Ruxolitinib—PLK3—pituitary gland—obesity	0.000969	0.00606	CbGeAlD
Ruxolitinib—PLK3—adipose tissue—obesity	0.000965	0.00604	CbGeAlD
Ruxolitinib—TAOK3—hindbrain—obesity	0.000949	0.00593	CbGeAlD
Ruxolitinib—Gastrointestinal haemorrhage—Sibutramine—obesity	0.000948	0.0121	CcSEcCtD
Ruxolitinib—ROCK1—respiratory system—obesity	0.000944	0.0059	CbGeAlD
Ruxolitinib—PRKCE—endocrine gland—obesity	0.000936	0.00585	CbGeAlD
Ruxolitinib—Dizziness—Benzphetamine—obesity	0.000935	0.012	CcSEcCtD
Ruxolitinib—NUAK2—islet of Langerhans—obesity	0.000928	0.0058	CbGeAlD
Ruxolitinib—DYRK1A—respiratory system—obesity	0.000921	0.00576	CbGeAlD
Ruxolitinib—JAK1—adrenal cortex—obesity	0.00092	0.00575	CbGeAlD
Ruxolitinib—Headache—Methamphetamine—obesity	0.000918	0.0117	CcSEcCtD
Ruxolitinib—BMPR2—respiratory system—obesity	0.000917	0.00574	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Phentermine—obesity	0.000909	0.0116	CcSEcCtD
Ruxolitinib—Fatigue—Phentermine—obesity	0.000908	0.0116	CcSEcCtD
Ruxolitinib—CAMK1—pituitary gland—obesity	0.000907	0.00567	CbGeAlD
Ruxolitinib—PRKG2—liver—obesity	0.000904	0.00565	CbGeAlD
Ruxolitinib—CAMK1—adipose tissue—obesity	0.000903	0.00565	CbGeAlD
Ruxolitinib—RPS6KA6—endocrine gland—obesity	0.0009	0.00563	CbGeAlD
Ruxolitinib—PLK1—endocrine gland—obesity	0.0009	0.00563	CbGeAlD
Ruxolitinib—Headache—Benzphetamine—obesity	0.000886	0.0113	CcSEcCtD
Ruxolitinib—DAPK2—adrenal cortex—obesity	0.000878	0.00549	CbGeAlD
Ruxolitinib—MARK2—adipose tissue—obesity	0.000876	0.00548	CbGeAlD
Ruxolitinib—PLK3—adrenal gland—obesity	0.000866	0.00541	CbGeAlD
Ruxolitinib—Thrombocytopenia—Cimetidine—obesity	0.000854	0.0109	CcSEcCtD
Ruxolitinib—Dizziness—Phendimetrazine—obesity	0.000852	0.0109	CcSEcCtD
Ruxolitinib—PRKCE—liver—obesity	0.000844	0.00528	CbGeAlD
Ruxolitinib—JAK1—cardiovascular system—obesity	0.00084	0.00525	CbGeAlD
Ruxolitinib—Alanine aminotransferase increased—Sibutramine—obesity	0.000836	0.0107	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Bupropion—obesity	0.000826	0.0106	CcSEcCtD
Ruxolitinib—MARK2—digestive system—obesity	0.000825	0.00516	CbGeAlD
Ruxolitinib—CAMK2G—respiratory system—obesity	0.000821	0.00513	CbGeAlD
Ruxolitinib—CLK2—adrenal cortex—obesity	0.000818	0.00511	CbGeAlD
Ruxolitinib—TAOK2—pituitary gland—obesity	0.000814	0.00509	CbGeAlD
Ruxolitinib—LRRK2—respiratory system—obesity	0.000814	0.00509	CbGeAlD
Ruxolitinib—PLK1—liver—obesity	0.000811	0.00507	CbGeAlD
Ruxolitinib—RPS6KA6—liver—obesity	0.000811	0.00507	CbGeAlD
Ruxolitinib—TAOK2—adipose tissue—obesity	0.000811	0.00507	CbGeAlD
Ruxolitinib—CAMK1—adrenal gland—obesity	0.00081	0.00506	CbGeAlD
Ruxolitinib—Headache—Phendimetrazine—obesity	0.000807	0.0103	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Diethylpropion—obesity	0.000791	0.0101	CcSEcCtD
Ruxolitinib—MARK2—adrenal gland—obesity	0.000786	0.00492	CbGeAlD
Ruxolitinib—HIPK2—cardiovascular system—obesity	0.000784	0.0049	CbGeAlD
Ruxolitinib—TYK2—islet of Langerhans—obesity	0.000768	0.0048	CbGeAlD
Ruxolitinib—MKNK2—islet of Langerhans—obesity	0.000758	0.00474	CbGeAlD
Ruxolitinib—IRAK1—islet of Langerhans—obesity	0.000758	0.00474	CbGeAlD
Ruxolitinib—Bone pain—Topiramate—obesity	0.000757	0.00968	CcSEcCtD
Ruxolitinib—Asthenia—Phentermine—obesity	0.000756	0.00966	CcSEcCtD
Ruxolitinib—Infestation NOS—Orlistat—obesity	0.000755	0.00965	CcSEcCtD
Ruxolitinib—Infestation—Orlistat—obesity	0.000755	0.00965	CcSEcCtD
Ruxolitinib—DAPK3—cardiovascular system—obesity	0.000753	0.00471	CbGeAlD
Ruxolitinib—Fatigue—Cimetidine—obesity	0.000752	0.00961	CcSEcCtD
Ruxolitinib—PLK3—endocrine gland—obesity	0.000751	0.00469	CbGeAlD
Ruxolitinib—Weight increased—Sibutramine—obesity	0.000745	0.00953	CcSEcCtD
Ruxolitinib—JAK3—adipose tissue—obesity	0.000745	0.00466	CbGeAlD
Ruxolitinib—JAK1—pituitary gland—obesity	0.000744	0.00465	CbGeAlD
Ruxolitinib—DCLK1—pituitary gland—obesity	0.000744	0.00465	CbGeAlD
Ruxolitinib—JAK1—adipose tissue—obesity	0.000741	0.00463	CbGeAlD
Ruxolitinib—DCLK1—adipose tissue—obesity	0.000741	0.00463	CbGeAlD
Ruxolitinib—Urinary tract infection—Orlistat—obesity	0.000734	0.00938	CcSEcCtD
Ruxolitinib—Dizziness—Phenylpropanolamine—obesity	0.000728	0.00931	CcSEcCtD
Ruxolitinib—TAOK2—adrenal gland—obesity	0.000727	0.00455	CbGeAlD
Ruxolitinib—CAMK1D—pituitary gland—obesity	0.000726	0.00454	CbGeAlD
Ruxolitinib—TYK2—respiratory system—obesity	0.000725	0.00453	CbGeAlD
Ruxolitinib—ROCK1—cardiovascular system—obesity	0.000723	0.00452	CbGeAlD
Ruxolitinib—CAMK1D—adipose tissue—obesity	0.000723	0.00452	CbGeAlD
Ruxolitinib—CYP3A4—Topiramate—obesity	0.000722	0.0834	CbGbCtD
Ruxolitinib—PHKG2—adipose tissue—obesity	0.000719	0.00449	CbGeAlD
Ruxolitinib—MKNK2—respiratory system—obesity	0.000716	0.00447	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Orlistat—obesity	0.000714	0.00913	CcSEcCtD
Ruxolitinib—Urinary tract infection—Sibutramine—obesity	0.00071	0.00908	CcSEcCtD
Ruxolitinib—DAPK2—adipose tissue—obesity	0.000707	0.00442	CbGeAlD
Ruxolitinib—DYRK1A—cardiovascular system—obesity	0.000705	0.00441	CbGeAlD
Ruxolitinib—BMPR2—cardiovascular system—obesity	0.000703	0.00439	CbGeAlD
Ruxolitinib—CAMK1—endocrine gland—obesity	0.000702	0.00439	CbGeAlD
Ruxolitinib—JAK3—digestive system—obesity	0.000702	0.00439	CbGeAlD
Ruxolitinib—STK16—pituitary gland—obesity	0.000698	0.00436	CbGeAlD
Ruxolitinib—JAK1—digestive system—obesity	0.000697	0.00436	CbGeAlD
Ruxolitinib—DCLK1—digestive system—obesity	0.000697	0.00436	CbGeAlD
Ruxolitinib—Dizziness—Phentermine—obesity	0.000696	0.0089	CcSEcCtD
Ruxolitinib—Haematuria—Sibutramine—obesity	0.000696	0.0089	CcSEcCtD
Ruxolitinib—STK16—adipose tissue—obesity	0.000695	0.00435	CbGeAlD
Ruxolitinib—HIPK2—adipose tissue—obesity	0.000691	0.00432	CbGeAlD
Ruxolitinib—Body temperature increased—Cimetidine—obesity	0.000689	0.00881	CcSEcCtD
Ruxolitinib—Epistaxis—Sibutramine—obesity	0.000689	0.00881	CcSEcCtD
Ruxolitinib—MARK2—endocrine gland—obesity	0.000682	0.00426	CbGeAlD
Ruxolitinib—Haemoglobin—Orlistat—obesity	0.000681	0.00871	CcSEcCtD
Ruxolitinib—Pancytopenia—Bupropion—obesity	0.000678	0.00867	CcSEcCtD
Ruxolitinib—Haemorrhage—Orlistat—obesity	0.000677	0.00866	CcSEcCtD
Ruxolitinib—PLK3—liver—obesity	0.000677	0.00423	CbGeAlD
Ruxolitinib—JAK3—adrenal gland—obesity	0.000668	0.00418	CbGeAlD
Ruxolitinib—DAPK3—pituitary gland—obesity	0.000667	0.00417	CbGeAlD
Ruxolitinib—JAK1—adrenal gland—obesity	0.000664	0.00415	CbGeAlD
Ruxolitinib—DCLK1—adrenal gland—obesity	0.000664	0.00415	CbGeAlD
Ruxolitinib—DAPK3—adipose tissue—obesity	0.000664	0.00415	CbGeAlD
Ruxolitinib—CLK2—pituitary gland—obesity	0.000661	0.00413	CbGeAlD
Ruxolitinib—PLK4—adrenal gland—obesity	0.00066	0.00413	CbGeAlD
Ruxolitinib—Headache—Phentermine—obesity	0.00066	0.00844	CcSEcCtD
Ruxolitinib—JAK2—respiratory system—obesity	0.00066	0.00412	CbGeAlD
Ruxolitinib—Haemoglobin—Sibutramine—obesity	0.000659	0.00843	CcSEcCtD
Ruxolitinib—CLK2—adipose tissue—obesity	0.000658	0.00411	CbGeAlD
Ruxolitinib—Haemorrhage—Sibutramine—obesity	0.000656	0.00838	CcSEcCtD
Ruxolitinib—STK16—digestive system—obesity	0.000654	0.00409	CbGeAlD
Ruxolitinib—HIPK2—digestive system—obesity	0.000651	0.00407	CbGeAlD
Ruxolitinib—Weight increased—Bupropion—obesity	0.00065	0.00831	CcSEcCtD
Ruxolitinib—CAMK1D—adrenal gland—obesity	0.000648	0.00405	CbGeAlD
Ruxolitinib—Weight decreased—Bupropion—obesity	0.000646	0.00826	CcSEcCtD
Ruxolitinib—PHKG2—adrenal gland—obesity	0.000645	0.00403	CbGeAlD
Ruxolitinib—Infestation—Bupropion—obesity	0.000637	0.00814	CcSEcCtD
Ruxolitinib—Infestation NOS—Bupropion—obesity	0.000637	0.00814	CcSEcCtD
Ruxolitinib—DAPK2—adrenal gland—obesity	0.000634	0.00396	CbGeAlD
Ruxolitinib—CAMK1—liver—obesity	0.000633	0.00396	CbGeAlD
Ruxolitinib—CAMK2G—cardiovascular system—obesity	0.000629	0.00393	CbGeAlD
Ruxolitinib—Asthenia—Cimetidine—obesity	0.000625	0.008	CcSEcCtD
Ruxolitinib—STK16—adrenal gland—obesity	0.000623	0.0039	CbGeAlD
Ruxolitinib—BMPR2—pituitary gland—obesity	0.000622	0.00389	CbGeAlD
Ruxolitinib—DYRK1A—adipose tissue—obesity	0.000622	0.00389	CbGeAlD
Ruxolitinib—HIPK2—adrenal gland—obesity	0.00062	0.00388	CbGeAlD
Ruxolitinib—MAP3K7—adrenal cortex—obesity	0.00062	0.00387	CbGeAlD
Ruxolitinib—BMPR2—adipose tissue—obesity	0.00062	0.00387	CbGeAlD
Ruxolitinib—Urinary tract infection—Bupropion—obesity	0.000619	0.00791	CcSEcCtD
Ruxolitinib—TAOK3—islet of Langerhans—obesity	0.000614	0.00384	CbGeAlD
Ruxolitinib—TYK2—adrenal cortex—obesity	0.000609	0.00381	CbGeAlD
Ruxolitinib—Dizziness—Diethylpropion—obesity	0.000606	0.00775	CcSEcCtD
Ruxolitinib—MKNK2—adrenal cortex—obesity	0.000601	0.00376	CbGeAlD
Ruxolitinib—Epistaxis—Bupropion—obesity	0.000601	0.00768	CcSEcCtD
Ruxolitinib—ROCK1—digestive system—obesity	0.0006	0.00375	CbGeAlD
Ruxolitinib—DAPK3—adrenal gland—obesity	0.000596	0.00373	CbGeAlD
Ruxolitinib—NUAK2—pituitary gland—obesity	0.000594	0.00372	CbGeAlD
Ruxolitinib—NUAK2—adipose tissue—obesity	0.000592	0.0037	CbGeAlD
Ruxolitinib—CLK2—adrenal gland—obesity	0.00059	0.00369	CbGeAlD
Ruxolitinib—Malnutrition—Orlistat—obesity	0.00059	0.00754	CcSEcCtD
Ruxolitinib—BMPR2—digestive system—obesity	0.000583	0.00365	CbGeAlD
Ruxolitinib—Flatulence—Orlistat—obesity	0.000581	0.00743	CcSEcCtD
Ruxolitinib—JAK3—endocrine gland—obesity	0.00058	0.00362	CbGeAlD
Ruxolitinib—TAOK3—respiratory system—obesity	0.00058	0.00362	CbGeAlD
Ruxolitinib—Dizziness—Cimetidine—obesity	0.000576	0.00737	CcSEcCtD
Ruxolitinib—JAK1—endocrine gland—obesity	0.000576	0.0036	CbGeAlD
Ruxolitinib—DCLK1—endocrine gland—obesity	0.000576	0.0036	CbGeAlD
Ruxolitinib—Haemoglobin—Bupropion—obesity	0.000574	0.00735	CcSEcCtD
Ruxolitinib—Headache—Diethylpropion—obesity	0.000574	0.00734	CcSEcCtD
Ruxolitinib—PLK4—endocrine gland—obesity	0.000572	0.00358	CbGeAlD
Ruxolitinib—Haemorrhage—Bupropion—obesity	0.000572	0.00731	CcSEcCtD
Ruxolitinib—Malnutrition—Sibutramine—obesity	0.000571	0.0073	CcSEcCtD
Ruxolitinib—TAOK2—liver—obesity	0.000569	0.00356	CbGeAlD
Ruxolitinib—Flatulence—Sibutramine—obesity	0.000562	0.00719	CcSEcCtD
Ruxolitinib—CAMK1D—endocrine gland—obesity	0.000562	0.00352	CbGeAlD
Ruxolitinib—PHKG2—endocrine gland—obesity	0.000559	0.0035	CbGeAlD
Ruxolitinib—DYRK1A—adrenal gland—obesity	0.000558	0.00349	CbGeAlD
Ruxolitinib—CAMK2G—pituitary gland—obesity	0.000557	0.00348	CbGeAlD
Ruxolitinib—BMPR2—adrenal gland—obesity	0.000556	0.00347	CbGeAlD
Ruxolitinib—TYK2—cardiovascular system—obesity	0.000555	0.00347	CbGeAlD
Ruxolitinib—CAMK2G—adipose tissue—obesity	0.000554	0.00347	CbGeAlD
Ruxolitinib—BMP2K—adipose tissue—obesity	0.000554	0.00347	CbGeAlD
Ruxolitinib—LRRK2—pituitary gland—obesity	0.000552	0.00345	CbGeAlD
Ruxolitinib—LRRK2—adipose tissue—obesity	0.000549	0.00344	CbGeAlD
Ruxolitinib—MKNK2—cardiovascular system—obesity	0.000548	0.00343	CbGeAlD
Ruxolitinib—Headache—Cimetidine—obesity	0.000546	0.00698	CcSEcCtD
Ruxolitinib—STK16—endocrine gland—obesity	0.000541	0.00338	CbGeAlD
Ruxolitinib—HIPK2—endocrine gland—obesity	0.000538	0.00336	CbGeAlD
Ruxolitinib—MAP3K3—adrenal cortex—obesity	0.000534	0.00334	CbGeAlD
Ruxolitinib—NUAK2—adrenal gland—obesity	0.000531	0.00332	CbGeAlD
Ruxolitinib—Anaemia—Sibutramine—obesity	0.000528	0.00674	CcSEcCtD
Ruxolitinib—CAMK2G—digestive system—obesity	0.000522	0.00326	CbGeAlD
Ruxolitinib—JAK1—liver—obesity	0.000519	0.00325	CbGeAlD
Ruxolitinib—DAPK3—endocrine gland—obesity	0.000517	0.00323	CbGeAlD
Ruxolitinib—CLK2—endocrine gland—obesity	0.000512	0.0032	CbGeAlD
Ruxolitinib—CAMK1D—liver—obesity	0.000507	0.00317	CbGeAlD
Ruxolitinib—JAK2—cardiovascular system—obesity	0.000505	0.00316	CbGeAlD
Ruxolitinib—PHKG2—liver—obesity	0.000504	0.00315	CbGeAlD
Ruxolitinib—MAP3K2—adipose tissue—obesity	0.000503	0.00315	CbGeAlD
Ruxolitinib—MAP3K7—pituitary gland—obesity	0.000501	0.00313	CbGeAlD
Ruxolitinib—MAP3K7—adipose tissue—obesity	0.000499	0.00312	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Orlistat—obesity	0.000499	0.00638	CcSEcCtD
Ruxolitinib—Malnutrition—Bupropion—obesity	0.000498	0.00636	CcSEcCtD
Ruxolitinib—BMP2K—adrenal gland—obesity	0.000497	0.00311	CbGeAlD
Ruxolitinib—CAMK2G—adrenal gland—obesity	0.000497	0.00311	CbGeAlD
Ruxolitinib—ROCK1—endocrine gland—obesity	0.000496	0.0031	CbGeAlD
Ruxolitinib—LRRK2—adrenal gland—obesity	0.000493	0.00308	CbGeAlD
Ruxolitinib—TYK2—pituitary gland—obesity	0.000492	0.00307	CbGeAlD
Ruxolitinib—Flatulence—Bupropion—obesity	0.00049	0.00627	CcSEcCtD
Ruxolitinib—TYK2—adipose tissue—obesity	0.00049	0.00306	CbGeAlD
Ruxolitinib—STK16—liver—obesity	0.000487	0.00305	CbGeAlD
Ruxolitinib—MAP3K3—cardiovascular system—obesity	0.000487	0.00304	CbGeAlD
Ruxolitinib—TAOK3—adrenal cortex—obesity	0.000486	0.00304	CbGeAlD
Ruxolitinib—MKNK2—pituitary gland—obesity	0.000485	0.00303	CbGeAlD
Ruxolitinib—HIPK2—liver—obesity	0.000485	0.00303	CbGeAlD
Ruxolitinib—DYRK1A—endocrine gland—obesity	0.000484	0.00303	CbGeAlD
Ruxolitinib—MKNK2—adipose tissue—obesity	0.000483	0.00302	CbGeAlD
Ruxolitinib—IRAK1—adipose tissue—obesity	0.000483	0.00302	CbGeAlD
Ruxolitinib—BMPR2—endocrine gland—obesity	0.000482	0.00301	CbGeAlD
Ruxolitinib—Infection—Orlistat—obesity	0.000478	0.00611	CcSEcCtD
Ruxolitinib—RET—pituitary gland—obesity	0.000473	0.00296	CbGeAlD
Ruxolitinib—Nervous system disorder—Orlistat—obesity	0.000472	0.00603	CcSEcCtD
Ruxolitinib—Skin disorder—Orlistat—obesity	0.000467	0.00598	CcSEcCtD
Ruxolitinib—DAPK3—liver—obesity	0.000466	0.00291	CbGeAlD
Ruxolitinib—Alanine aminotransferase increased—Topiramate—obesity	0.000464	0.00594	CcSEcCtD
Ruxolitinib—Infection—Sibutramine—obesity	0.000463	0.00592	CcSEcCtD
Ruxolitinib—CLK2—liver—obesity	0.000461	0.00289	CbGeAlD
Ruxolitinib—TYK2—digestive system—obesity	0.000461	0.00288	CbGeAlD
Ruxolitinib—Anaemia—Bupropion—obesity	0.00046	0.00588	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Sibutramine—obesity	0.000456	0.00583	CcSEcCtD
Ruxolitinib—MKNK2—digestive system—obesity	0.000455	0.00284	CbGeAlD
Ruxolitinib—Skin disorder—Sibutramine—obesity	0.000452	0.00578	CcSEcCtD
Ruxolitinib—MAP3K2—adrenal gland—obesity	0.000452	0.00282	CbGeAlD
Ruxolitinib—JAK2—pituitary gland—obesity	0.000447	0.0028	CbGeAlD
Ruxolitinib—MAP3K7—adrenal gland—obesity	0.000447	0.0028	CbGeAlD
Ruxolitinib—ROCK1—liver—obesity	0.000447	0.0028	CbGeAlD
Ruxolitinib—JAK2—adipose tissue—obesity	0.000446	0.00279	CbGeAlD
Ruxolitinib—TAOK3—cardiovascular system—obesity	0.000444	0.00278	CbGeAlD
Ruxolitinib—RET—digestive system—obesity	0.000444	0.00277	CbGeAlD
Ruxolitinib—TYK2—adrenal gland—obesity	0.000439	0.00275	CbGeAlD
Ruxolitinib—DYRK1A—liver—obesity	0.000436	0.00273	CbGeAlD
Ruxolitinib—BMPR2—liver—obesity	0.000434	0.00272	CbGeAlD
Ruxolitinib—MKNK2—adrenal gland—obesity	0.000434	0.00271	CbGeAlD
Ruxolitinib—IRAK1—adrenal gland—obesity	0.000434	0.00271	CbGeAlD
Ruxolitinib—Pancytopenia—Topiramate—obesity	0.000432	0.00552	CcSEcCtD
Ruxolitinib—CAMK2G—endocrine gland—obesity	0.000431	0.0027	CbGeAlD
Ruxolitinib—BMP2K—endocrine gland—obesity	0.000431	0.0027	CbGeAlD
Ruxolitinib—MAP3K3—pituitary gland—obesity	0.000431	0.0027	CbGeAlD
Ruxolitinib—MAP3K3—adipose tissue—obesity	0.000429	0.00269	CbGeAlD
Ruxolitinib—LRRK2—endocrine gland—obesity	0.000427	0.00267	CbGeAlD
Ruxolitinib—Neutropenia—Topiramate—obesity	0.000425	0.00544	CcSEcCtD
Ruxolitinib—RET—adrenal gland—obesity	0.000423	0.00264	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Bupropion—obesity	0.000421	0.00538	CcSEcCtD
Ruxolitinib—JAK2—digestive system—obesity	0.000419	0.00262	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Orlistat—obesity	0.000416	0.00531	CcSEcCtD
Ruxolitinib—NUAK2—liver—obesity	0.000415	0.0026	CbGeAlD
Ruxolitinib—Fatigue—Orlistat—obesity	0.000415	0.00531	CcSEcCtD
Ruxolitinib—Weight increased—Topiramate—obesity	0.000414	0.00529	CcSEcCtD
Ruxolitinib—Weight decreased—Topiramate—obesity	0.000412	0.00526	CcSEcCtD
Ruxolitinib—Infestation—Topiramate—obesity	0.000406	0.00519	CcSEcCtD
Ruxolitinib—Infestation NOS—Topiramate—obesity	0.000406	0.00519	CcSEcCtD
Ruxolitinib—Infection—Bupropion—obesity	0.000403	0.00516	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Sibutramine—obesity	0.000402	0.00514	CcSEcCtD
Ruxolitinib—JAK2—adrenal gland—obesity	0.0004	0.0025	CbGeAlD
Ruxolitinib—Nervous system disorder—Bupropion—obesity	0.000398	0.00509	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Bupropion—obesity	0.000398	0.00508	CcSEcCtD
Ruxolitinib—Skin disorder—Bupropion—obesity	0.000394	0.00504	CcSEcCtD
Ruxolitinib—Urinary tract infection—Topiramate—obesity	0.000394	0.00504	CcSEcCtD
Ruxolitinib—TAOK3—pituitary gland—obesity	0.000393	0.00246	CbGeAlD
Ruxolitinib—MAP3K2—endocrine gland—obesity	0.000392	0.00245	CbGeAlD
Ruxolitinib—TAOK3—adipose tissue—obesity	0.000391	0.00245	CbGeAlD
Ruxolitinib—CAMK2G—liver—obesity	0.000389	0.00243	CbGeAlD
Ruxolitinib—BMP2K—liver—obesity	0.000389	0.00243	CbGeAlD
Ruxolitinib—Haematuria—Topiramate—obesity	0.000387	0.00495	CcSEcCtD
Ruxolitinib—LRRK2—liver—obesity	0.000385	0.00241	CbGeAlD
Ruxolitinib—MAP3K3—adrenal gland—obesity	0.000385	0.00241	CbGeAlD
Ruxolitinib—Epistaxis—Topiramate—obesity	0.000383	0.00489	CcSEcCtD
Ruxolitinib—TYK2—endocrine gland—obesity	0.000381	0.00238	CbGeAlD
Ruxolitinib—Body temperature increased—Orlistat—obesity	0.00038	0.00486	CcSEcCtD
Ruxolitinib—MKNK2—endocrine gland—obesity	0.000376	0.00235	CbGeAlD
Ruxolitinib—TAOK3—digestive system—obesity	0.000369	0.0023	CbGeAlD
Ruxolitinib—Body temperature increased—Sibutramine—obesity	0.000368	0.00471	CcSEcCtD
Ruxolitinib—RET—endocrine gland—obesity	0.000367	0.00229	CbGeAlD
Ruxolitinib—Haemoglobin—Topiramate—obesity	0.000366	0.00468	CcSEcCtD
Ruxolitinib—Haemorrhage—Topiramate—obesity	0.000364	0.00466	CcSEcCtD
Ruxolitinib—MAP3K2—liver—obesity	0.000353	0.00221	CbGeAlD
Ruxolitinib—TAOK3—adrenal gland—obesity	0.000351	0.0022	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Bupropion—obesity	0.000351	0.00448	CcSEcCtD
Ruxolitinib—Fatigue—Bupropion—obesity	0.00035	0.00448	CcSEcCtD
Ruxolitinib—MAP3K7—liver—obesity	0.00035	0.00219	CbGeAlD
Ruxolitinib—JAK2—endocrine gland—obesity	0.000347	0.00217	CbGeAlD
Ruxolitinib—Asthenia—Orlistat—obesity	0.000345	0.00442	CcSEcCtD
Ruxolitinib—TYK2—liver—obesity	0.000343	0.00215	CbGeAlD
Ruxolitinib—Pruritus—Orlistat—obesity	0.000341	0.00435	CcSEcCtD
Ruxolitinib—MKNK2—liver—obesity	0.000339	0.00212	CbGeAlD
Ruxolitinib—IRAK1—liver—obesity	0.000339	0.00212	CbGeAlD
Ruxolitinib—Asthenia—Sibutramine—obesity	0.000334	0.00427	CcSEcCtD
Ruxolitinib—MAP3K3—endocrine gland—obesity	0.000334	0.00209	CbGeAlD
Ruxolitinib—Pruritus—Sibutramine—obesity	0.00033	0.00421	CcSEcCtD
Ruxolitinib—Body temperature increased—Bupropion—obesity	0.000321	0.0041	CcSEcCtD
Ruxolitinib—Dizziness—Orlistat—obesity	0.000318	0.00407	CcSEcCtD
Ruxolitinib—Malnutrition—Topiramate—obesity	0.000317	0.00405	CcSEcCtD
Ruxolitinib—JAK2—liver—obesity	0.000312	0.00195	CbGeAlD
Ruxolitinib—Flatulence—Topiramate—obesity	0.000312	0.00399	CcSEcCtD
Ruxolitinib—Dizziness—Sibutramine—obesity	0.000308	0.00394	CcSEcCtD
Ruxolitinib—TAOK3—endocrine gland—obesity	0.000305	0.0019	CbGeAlD
Ruxolitinib—Headache—Orlistat—obesity	0.000302	0.00386	CcSEcCtD
Ruxolitinib—MAP3K3—liver—obesity	0.000301	0.00188	CbGeAlD
Ruxolitinib—Anaemia—Topiramate—obesity	0.000293	0.00375	CcSEcCtD
Ruxolitinib—Headache—Sibutramine—obesity	0.000292	0.00373	CcSEcCtD
Ruxolitinib—Asthenia—Bupropion—obesity	0.000291	0.00373	CcSEcCtD
Ruxolitinib—Pruritus—Bupropion—obesity	0.000287	0.00367	CcSEcCtD
Ruxolitinib—TAOK3—liver—obesity	0.000275	0.00172	CbGeAlD
Ruxolitinib—Dizziness—Bupropion—obesity	0.000269	0.00343	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Topiramate—obesity	0.000268	0.00343	CcSEcCtD
Ruxolitinib—Infection—Topiramate—obesity	0.000257	0.00329	CcSEcCtD
Ruxolitinib—Headache—Bupropion—obesity	0.000254	0.00325	CcSEcCtD
Ruxolitinib—Nervous system disorder—Topiramate—obesity	0.000254	0.00324	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Topiramate—obesity	0.000253	0.00324	CcSEcCtD
Ruxolitinib—Skin disorder—Topiramate—obesity	0.000251	0.00321	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Topiramate—obesity	0.000223	0.00286	CcSEcCtD
Ruxolitinib—Fatigue—Topiramate—obesity	0.000223	0.00285	CcSEcCtD
Ruxolitinib—Body temperature increased—Topiramate—obesity	0.000205	0.00261	CcSEcCtD
Ruxolitinib—Asthenia—Topiramate—obesity	0.000186	0.00237	CcSEcCtD
Ruxolitinib—Pruritus—Topiramate—obesity	0.000183	0.00234	CcSEcCtD
Ruxolitinib—Dizziness—Topiramate—obesity	0.000171	0.00219	CcSEcCtD
Ruxolitinib—Headache—Topiramate—obesity	0.000162	0.00207	CcSEcCtD
Ruxolitinib—CYP3A4—digestive system—obesity	0.000112	0.0007	CbGeAlD
Ruxolitinib—CYP3A4—endocrine gland—obesity	9.25e-05	0.000578	CbGeAlD
Ruxolitinib—CYP3A4—liver—obesity	8.34e-05	0.000522	CbGeAlD
Ruxolitinib—CYP3A4—Metabolism—STS—obesity	2.01e-06	7.87e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HK2—obesity	2.01e-06	7.87e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—INS—obesity	2e-06	7.84e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—STAT3—obesity	2e-06	7.82e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IGF1—obesity	2e-06	7.82e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—TYK2—obesity	2e-06	7.81e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—AKT2—obesity	2e-06	7.81e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—RHOA—obesity	1.98e-06	7.75e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PIK3CD—obesity	1.98e-06	7.73e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—PIK3CA—obesity	1.97e-06	7.71e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCL2—obesity	1.97e-06	7.71e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HTR2A—obesity	1.97e-06	7.71e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MMP9—obesity	1.97e-06	7.7e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—C3—obesity	1.97e-06	7.7e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPARD—obesity	1.97e-06	7.7e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PIK3R1—obesity	1.96e-06	7.67e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NOS3—obesity	1.96e-06	7.67e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PIK3CB—obesity	1.96e-06	7.67e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MTOR—obesity	1.96e-06	7.67e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—SERPINE1—obesity	1.95e-06	7.64e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—STAT3—obesity	1.94e-06	7.58e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IGF1—obesity	1.94e-06	7.58e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—AKT2—obesity	1.94e-06	7.57e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MMP9—obesity	1.94e-06	7.57e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SLC27A1—obesity	1.93e-06	7.54e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PIK3CD—obesity	1.92e-06	7.5e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MAPK8—obesity	1.91e-06	7.49e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—AKT1—obesity	1.91e-06	7.47e-06	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—PIK3CA—obesity	1.9e-06	7.44e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TYK2—obesity	1.9e-06	7.44e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—AKT1—obesity	1.9e-06	7.42e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—SERPINE1—obesity	1.9e-06	7.42e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL6—obesity	1.89e-06	7.4e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—FABP4—obesity	1.89e-06	7.4e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GLUL—obesity	1.89e-06	7.4e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MYC—obesity	1.89e-06	7.4e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TGFB1—obesity	1.89e-06	7.38e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—RHOA—obesity	1.88e-06	7.37e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MAPK8—obesity	1.88e-06	7.37e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—AKT1—obesity	1.88e-06	7.35e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IRS2—obesity	1.87e-06	7.32e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AGT—obesity	1.87e-06	7.32e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PIK3R1—obesity	1.87e-06	7.3e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NOS3—obesity	1.87e-06	7.3e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—AKT1—obesity	1.86e-06	7.28e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CD—obesity	1.86e-06	7.28e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—STAT3—obesity	1.84e-06	7.22e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—SERPINE1—obesity	1.84e-06	7.2e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—LEP—obesity	1.83e-06	7.17e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—APOE—obesity	1.83e-06	7.17e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—RHOA—obesity	1.83e-06	7.16e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—IL6—obesity	1.82e-06	7.11e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CAV1—obesity	1.82e-06	7.1e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—APOA1—obesity	1.81e-06	7.09e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PIK3R1—obesity	1.81e-06	7.09e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NOS3—obesity	1.81e-06	7.09e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PIK3CB—obesity	1.81e-06	7.08e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MTOR—obesity	1.81e-06	7.08e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL1B—obesity	1.81e-06	7.07e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTGS2—obesity	1.79e-06	7.01e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—UCP3—obesity	1.79e-06	7.01e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ECHS1—obesity	1.79e-06	7.01e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—UCP2—obesity	1.79e-06	7.01e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HSD11B1—obesity	1.79e-06	7.01e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TYK2—obesity	1.79e-06	7e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—RHOA—obesity	1.77e-06	6.94e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ADH1B—obesity	1.76e-06	6.9e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3R1—obesity	1.76e-06	6.87e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NOS3—obesity	1.76e-06	6.87e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—STAT3—obesity	1.75e-06	6.85e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ESR1—obesity	1.75e-06	6.84e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—IL6—obesity	1.75e-06	6.83e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—AKT1—obesity	1.74e-06	6.82e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ACSL1—obesity	1.74e-06	6.79e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPARGC1B—obesity	1.74e-06	6.79e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GPAM—obesity	1.74e-06	6.79e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PRKCB—obesity	1.73e-06	6.76e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—F2—obesity	1.73e-06	6.76e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—PIK3CA—obesity	1.73e-06	6.75e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PIK3CB—obesity	1.72e-06	6.74e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MTOR—obesity	1.72e-06	6.74e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—STAT3—obesity	1.72e-06	6.73e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MYC—obesity	1.71e-06	6.71e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—TGFB1—obesity	1.71e-06	6.69e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—BAD—obesity	1.71e-06	6.68e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HADH—obesity	1.69e-06	6.59e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PCK1—obesity	1.69e-06	6.59e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—FADS1—obesity	1.69e-06	6.59e-06	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IL6—obesity	1.68e-06	6.59e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—AKT1—obesity	1.68e-06	6.55e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MTOR—obesity	1.67e-06	6.54e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PIK3CB—obesity	1.67e-06	6.54e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MAPK8—obesity	1.66e-06	6.48e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CG—obesity	1.65e-06	6.47e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ACP5—obesity	1.64e-06	6.41e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IRS1—obesity	1.63e-06	6.39e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MYC—obesity	1.63e-06	6.36e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—PIK3CA—obesity	1.62e-06	6.35e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TGFB1—obesity	1.62e-06	6.35e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CB—obesity	1.62e-06	6.34e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MTOR—obesity	1.62e-06	6.34e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—AKT1—obesity	1.61e-06	6.3e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—PIK3CA—obesity	1.6e-06	6.28e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MYC—obesity	1.6e-06	6.26e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—G6PD—obesity	1.6e-06	6.25e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TGFB1—obesity	1.6e-06	6.24e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SREBF2—obesity	1.58e-06	6.17e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HK1—obesity	1.58e-06	6.17e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—PIK3CA—obesity	1.58e-06	6.17e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—POMC—obesity	1.57e-06	6.16e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—INS—obesity	1.57e-06	6.12e-06	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—AKT1—obesity	1.55e-06	6.08e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCL2—obesity	1.54e-06	6.02e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—PIK3CA—obesity	1.53e-06	5.98e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—IL6—obesity	1.53e-06	5.98e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—LPA—obesity	1.52e-06	5.96e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—STAT3—obesity	1.51e-06	5.92e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IGF1—obesity	1.51e-06	5.92e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AKT2—obesity	1.51e-06	5.92e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MMP9—obesity	1.5e-06	5.86e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—LPIN1—obesity	1.49e-06	5.83e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOA5—obesity	1.46e-06	5.72e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MAPK8—obesity	1.46e-06	5.69e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PIK3CA—obesity	1.46e-06	5.69e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CD—obesity	1.45e-06	5.69e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MMP9—obesity	1.45e-06	5.68e-06	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—PIK3CA—obesity	1.44e-06	5.63e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL6—obesity	1.44e-06	5.62e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SERPINE1—obesity	1.44e-06	5.62e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL6—obesity	1.42e-06	5.56e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MAPK8—obesity	1.41e-06	5.53e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MMP9—obesity	1.41e-06	5.51e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—AKT1—obesity	1.41e-06	5.51e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TYK2—obesity	1.4e-06	5.47e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—STAT3—obesity	1.4e-06	5.47e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL6—obesity	1.4e-06	5.46e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CLOCK—obesity	1.39e-06	5.45e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SLC22A1—obesity	1.39e-06	5.45e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—RHOA—obesity	1.39e-06	5.43e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—PIK3CA—obesity	1.38e-06	5.4e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3R1—obesity	1.37e-06	5.37e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NOS3—obesity	1.37e-06	5.37e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MAPK8—obesity	1.37e-06	5.36e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GLP1R—obesity	1.36e-06	5.31e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SULT2A1—obesity	1.36e-06	5.31e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—PIK3CA—obesity	1.36e-06	5.31e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL6—obesity	1.35e-06	5.3e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—DPYD—obesity	1.34e-06	5.23e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—STAT3—obesity	1.33e-06	5.21e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—AKT1—obesity	1.33e-06	5.19e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—AKT1—obesity	1.31e-06	5.13e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—PIK3CA—obesity	1.31e-06	5.11e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MYC—obesity	1.3e-06	5.08e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—TGFB1—obesity	1.3e-06	5.07e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—STAT3—obesity	1.29e-06	5.05e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—IL6—obesity	1.29e-06	5.04e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—AKT1—obesity	1.29e-06	5.04e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PRKAR2B—obesity	1.29e-06	5.03e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—DCN—obesity	1.28e-06	5e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MTOR—obesity	1.27e-06	4.96e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CB—obesity	1.27e-06	4.96e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—STAT3—obesity	1.25e-06	4.9e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—AKT1—obesity	1.25e-06	4.89e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CPT1A—obesity	1.24e-06	4.86e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MYC—obesity	1.24e-06	4.84e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TGFB1—obesity	1.23e-06	4.83e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL6—obesity	1.22e-06	4.78e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NAMPT—obesity	1.22e-06	4.77e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—LIPC—obesity	1.21e-06	4.74e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GCK—obesity	1.21e-06	4.74e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOC3—obesity	1.2e-06	4.71e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL6—obesity	1.2e-06	4.7e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MYC—obesity	1.2e-06	4.7e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TGFB1—obesity	1.2e-06	4.69e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PIK3CA—obesity	1.19e-06	4.67e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—AKT1—obesity	1.19e-06	4.65e-06	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—AKT1—obesity	1.18e-06	4.6e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CETP—obesity	1.17e-06	4.57e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MYC—obesity	1.16e-06	4.56e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TGFB1—obesity	1.16e-06	4.54e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL6—obesity	1.16e-06	4.53e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SDC1—obesity	1.15e-06	4.52e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AKR1C3—obesity	1.14e-06	4.45e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—AKT1—obesity	1.13e-06	4.41e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SCARB1—obesity	1.12e-06	4.38e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—AKT1—obesity	1.11e-06	4.34e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PIK3CA—obesity	1.1e-06	4.31e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MMP9—obesity	1.1e-06	4.31e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SREBF1—obesity	1.09e-06	4.25e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MAPK8—obesity	1.07e-06	4.19e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—AKT1—obesity	1.07e-06	4.18e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL6—obesity	1.06e-06	4.14e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GOT2—obesity	1.06e-06	4.13e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PIK3CA—obesity	1.05e-06	4.11e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—FASN—obesity	1.03e-06	4.04e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—BCHE—obesity	1.03e-06	4.03e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PIK3CA—obesity	1.02e-06	3.99e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP2E1—obesity	9.93e-07	3.89e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CA—obesity	9.88e-07	3.87e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NQO1—obesity	9.82e-07	3.84e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—STAT3—obesity	9.79e-07	3.83e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—IL6—obesity	9.77e-07	3.82e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—AKT1—obesity	9.76e-07	3.82e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SLC2A4—obesity	9.41e-07	3.68e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GCG—obesity	9.41e-07	3.68e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL6—obesity	9.3e-07	3.64e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYCS—obesity	9.29e-07	3.64e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GOT1—obesity	9.12e-07	3.57e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GGT1—obesity	9.12e-07	3.57e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MYC—obesity	9.1e-07	3.56e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TGFB1—obesity	9.08e-07	3.55e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL6—obesity	9.02e-07	3.53e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—AKT1—obesity	9.01e-07	3.52e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NCOA1—obesity	8.98e-07	3.51e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—STK11—obesity	8.85e-07	3.46e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP19A1—obesity	8.85e-07	3.46e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL6—obesity	8.75e-07	3.42e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—AKT1—obesity	8.58e-07	3.36e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—AKT1—obesity	8.32e-07	3.26e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—COMT—obesity	8.23e-07	3.22e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPARGC1A—obesity	8.11e-07	3.17e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GNB3—obesity	8.11e-07	3.17e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HMOX1—obesity	8.08e-07	3.16e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—AKT1—obesity	8.07e-07	3.16e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GNAS—obesity	7.9e-07	3.09e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOB—obesity	7.74e-07	3.03e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CA—obesity	7.72e-07	3.02e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—LPL—obesity	7.39e-07	2.89e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GPX1—obesity	7.21e-07	2.82e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CD36—obesity	7.02e-07	2.75e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL6—obesity	6.84e-07	2.68e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—MTHFR—obesity	6.65e-07	2.6e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPARA—obesity	6.53e-07	2.55e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AGT—obesity	6.32e-07	2.47e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AKT1—obesity	6.31e-07	2.47e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOE—obesity	6.19e-07	2.42e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CAV1—obesity	6.14e-07	2.4e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOA1—obesity	6.12e-07	2.39e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CG—obesity	5.59e-07	2.19e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPARG—obesity	5.39e-07	2.11e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—POMC—obesity	5.32e-07	2.08e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—INS—obesity	5.29e-07	2.07e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CD—obesity	4.91e-07	1.92e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALB—obesity	4.85e-07	1.9e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3R1—obesity	4.64e-07	1.82e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NOS3—obesity	4.64e-07	1.82e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CB—obesity	4.28e-07	1.68e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTGS2—obesity	4.24e-07	1.66e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CA—obesity	2.61e-07	1.02e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AKT1—obesity	2.13e-07	8.34e-07	CbGpPWpGaD
